Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wharton's jelly mesenchymal stem cell
- Development stage
- Unknown
- Lead developer
- Shenzhen Boya Ganzi Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Wharton's jelly mesenchymal stem cells (WJ-MSCs) are multipotent stem cells harvested from the gelatinous tissue of the umbilical cord. Developed by Shenzhen Boya Ganzi Pharmaceutical (a subsidiary of Boyalife Group) for the treatment of knee osteoarthritis, this cell therapy leverages the immunomodulatory and regenerative properties of MSCs. When administered via intra-articular injection, WJ-MSCs exert therapeutic effects primarily through paracrine signaling, secreting a variety of anti-inflammatory cytokines and growth factors that modulate the joint microenvironment. These cells help to suppress synovial inflammation, inhibit the activity of pro-inflammatory macrophages and T-cells, and promote the proliferation of chondrocytes and the synthesis of extracellular matrix components. This approach aims to slow the progression of joint degeneration and facilitate the repair of damaged articular cartilage.
- Other names
- WJ-MSCWharton's jelly-derived mesenchymal stem cellsHuman umbilical cord mesenchymal stem cells人脐带间充质干细胞注射液
Beyond the preview
Go deeper on wharton's jelly mesenchymal stem cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wharton's jelly mesenchymal stem cell.